Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study shows cemiplimab effective for advanced skin cancer

NCT ID NCT03836105

Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked 287 people with advanced skin cancer (squamous cell or basal cell) to see how well the drug cemiplimab works outside of a clinical trial. Researchers measured tumor shrinkage, survival, and side effects. The goal was to understand real-world effectiveness and safety of this treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

287 people

The number who actually took part.

Started

Jun 2019

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients in this study will include men and women ≥18 years of age who have recently initiated, or who plan to initiate treatment with commercially available cemiplimab for laCSCC/mCSCC or laBCC/mBCC in a real-world setting.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Eligible for treatment with and prescribed cemiplimab for advanced CSCC or advanced BCC in accordance with approved prescribing information as described in the protocol Key Exclusion Criteria: * Receiving cemiplimab for an indication other than advanced CSCC or advanced BCC * Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study * Patients concurrently participating in any study including administration of any investigational drug (including cemiplimab) or procedure (including survival follow up) Note: Other protocol defined Inclusion/Exclusion Criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced basal cell carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Basal cell carcinoma Cutaneous squamous cell carcinoma

Contacts and locations

Locations

  • Asante Rogue Regional Medical Center

    Medford, Oregon, 97504, United States

  • Baltimore Veterans Affairs Medical Center

    Baltimore, Maryland, 21201, United States

  • CARTI Cancer Center

    Little Rock, Arkansas, 72205, United States

  • CHRISTUS Highland Cancer Treatment Center

    Shreveport, Louisiana, 71105, United States

  • Charleston Hematology Oncology Associates, PA

    Charleston, South Carolina, 29414, United States

  • Clinical Research Center of the Carolinas

    Charleston, South Carolina, 29407, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Dignity Health St. Joseph's Hospital and Medical Center

    Phoenix, Arizona, 85013, United States

  • Durham VA Medical Center

    Durham, North Carolina, 27705, United States

  • FDI Clinical Research

    San Juan, 00927, Puerto Rico

  • Frederick Health

    Frederick, Maryland, 21702, United States

  • Harbor-UCLA/LA Biomedical Research Institute

    Los Angeles, California, 90502, United States

  • Inova Schar Cancer Institute

    Fairfax, Virginia, 22031, United States

  • Integrity Clinical Research

    Delray Beach, Florida, 33745, United States

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts, 01805, United States

  • Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital

    Thomasville, Georgia, 31792, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida, 33176, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Montefiore Hospital

    The Bronx, New York, 10461, United States

  • New York Cancer and Blood Specialists

    Port Jefferson Station, New York, 11776, United States

  • NorthShore University HealthSystem

    Evanston, Illinois, 60201, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Oncology Specialists of Charlotte, PA

    Charlotte, North Carolina, 28204, United States

  • Oncology Specialties, PC - Clearview Cancer Institute

    Huntsville, Alabama, 35805, United States

  • Optum Cancer Care

    Las Vegas, Nevada, 89102, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Pan-American Center for Oncology Trials, LLC

    Rio Piedras, 00902, Puerto Rico

  • Regeneron Research Facility

    Stanford, California, 94063, United States

  • Regeneron Research Facility

    Largo, Florida, 33770, United States

  • Regeneron Research Facility

    Miami, Florida, 33156, United States

  • Regeneron Research Facility

    Elizabeth, New Jersey, 07202, United States

  • Regeneron Research Facility

    New York, New York, 10016, United States

  • Regeneron Research Facility

    New York, New York, 10032, United States

  • Regeneron Research Facility

    Nyack, New York, 10960, United States

  • Regional Cancer Care Associates, LLC

    Manchester, Connecticut, 06040, United States

  • Reid Oncology Association

    Richmond, Indiana, 47374, United States

  • Renovatio Clinical

    The Woodlands, Texas, 77380, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14203, United States

  • Southeast Nebraska Hematology & Oncology Consultants, PC

    Lincoln, Nebraska, 68510, United States

  • St. Luke's University Health Network

    Bethlehem, Pennsylvania, 18015, United States

  • St. Mary's Medical Center

    San Francisco, California, 94117, United States

  • Texas Oncology

    Dallas, Texas, 75246, United States

  • Texas Oncology-Amarillo Cancer Center

    Amarillo, Texas, 79106, United States

  • The Melanoma and Skin Cancer Institute

    Englewood, Colorado, 80113, United States

  • University of California San Diego

    La Jolla, California, 92037, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Tennessee Medical Center

    Knoxville, Tennessee, 37920, United States

  • University of Texas Southwestern

    Dallas, Texas, 75390, United States

  • University of Vermont

    Burlington, Vermont, 05401, United States

  • University of Virginia

    Charlottesville, Virginia, 22908, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.